The ACTH fragment that kept the brain-boosting effects and dropped the cortisol—a Russian pharmaceutical nootropic with three decades of clinical use and almost no Western validation

Your pituitary gland makes a hormone called ACTH that tells your adrenal glands to produce cortisol—the body's primary stress response molecule. But buried within ACTH's thirty-nine amino acid sequence is a seven-amino-acid fragment, ACTH(4-10), that does something entirely different: it enhances learning, attention, and memory without touching cortisol at all. Semax is a synthetic, stabilized version of that fragment.

Developed at the Institute of Molecular Genetics in Moscow in the 1990s, Semax became one of Russia's first approved peptide nootropics—a nasal spray prescribed for cognitive enhancement (0.1% solution) and as an emergency treatment for acute ischemic stroke (1% solution, hospital use). It has been a registered pharmaceutical in Russia for three decades. In the Western peptide community, it is one of the most popular nootropics, praised for improved focus, verbal fluency, and reduced anxiety.

The evidence picture is genuinely interesting. Semax's mechanism is well-characterized across multiple independent labs. It robustly increases BDNF and NGF in the hippocampus. It modulates melanocortin receptors (MC3R/MC4R) that regulate learning and memory. It reduces neuroinflammation in stroke models. The animal data is extensive, consistent, and replicated. What is missing is rigorous, English-language, placebo-controlled human trial data. Russian pharmaceutical approval implies controlled clinical trials, but these data have never been published in Western journals with sufficient detail for independent assessment.

Quick Facts: Semax at a Glance

What Is Semax?

Pronunciation: SEH-max

There is a reason your brain has its own set of hormones—distinct from the ones that regulate your metabolism, your immune system, or your reproductive cycle. One of those brain hormones is ACTH, a thirty-nine-amino-acid peptide that the pituitary gland releases during stress to tell the adrenal glands to produce cortisol. But researchers discovered decades ago that a small piece of ACTH—just amino acids 4 through 10—does something cortisol has nothing to do with: it enhances learning and memory.

Semax is a synthetic version of that fragment, stabilized with a tripeptide tail (Pro-Gly-Pro) to resist the aminopeptidase enzymes that would otherwise destroy it within minutes. The stabilization trick was invented at the Institute of Molecular Genetics in Moscow, and the same tail appears on Selank—Semax's "anxiolytic twin" from the same laboratory. Together, Semax and Selank represent a platform approach to peptide drug design: take a biologically active fragment, add Pro-Gly-Pro for stability, and deliver it intranasally to bypass the blood-brain barrier.

The result is a compound that dissociates the neurotropic activity of ACTH from its endocrine activity. Semax enhances BDNF, modulates melanocortin receptors, increases dopamine turnover, and reduces neuroinflammation—all without raising cortisol, suppressing the immune system, or causing any of the other consequences of HPA axis activation. This pharmacological dissociation is Semax's most important property and the basis for its clinical utility.

Origins and Discovery

Semax emerged from a Soviet-era research program at the Institute of Molecular Genetics (IMG) of the Russian Academy of Sciences in Moscow. In the 1970s and 1980s, researchers including Nikolai Myasoedov investigated the cognitive effects of ACTH fragments—a line of research that was simultaneously active in Western labs (ORG 2766, ebiratide) but reached clinical fruition only in Russia.

The key insight was that ACTH's cognitive effects could be isolated in a short fragment (residues 4-10) that had no adrenal activity. The challenge was metabolic instability—the naked heptapeptide was degraded within minutes by aminopeptidases. The Pro-Gly-Pro stabilization solution, developed at the IMG, extended the half-life approximately fifteen-fold, making intranasal delivery feasible.

Semax received Russian pharmaceutical approval in 1996—first as a 0.1% nasal spray for cognitive enhancement (marketed for memory, attention, and "asthenia"), and subsequently as a 1% solution for emergency treatment of acute ischemic stroke (hospital use). The 1% stroke formulation implied that controlled clinical trials had been conducted in stroke patients, but these data were published primarily in Russian journals and are not available for English-language review.

By 2026, Semax has been in continuous pharmaceutical use in Russia for thirty years—longer than most peptides in the Western community have even existed as research chemicals. This length of clinical experience is both its strongest argument and its greatest frustration: three decades of use should have generated an enormous amount of safety and efficacy data, but almost none of it has been published in formats accessible to Western science.

Mechanism of Action

BDNF and NGF Upregulation

Semax robustly increases brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the hippocampus, cortex, and basal forebrain (PMID 20359812, 18577377). BDNF is the master regulator of synaptic plasticity—the molecular basis of learning and memory. NGF supports cholinergic neurons in the basal forebrain, the same population that degenerates in Alzheimer's disease. Multiple independent labs have confirmed Semax-induced BDNF upregulation, making this the best-replicated mechanism.

Melanocortin Receptor Signaling (MC3R/MC4R)

As an ACTH(4-10) analog, Semax interacts with melanocortin receptors MC3R and MC4R in the brain. Unlike full-length ACTH, Semax does not activate MC2R (the adrenal cortisol receptor)—this is the pharmacological dissociation that makes Semax a nootropic rather than a stress hormone. MC4R activation in the hippocampus modulates memory consolidation, attention, and executive function (PMID 15896883). MC3R activation influences neuronal energy metabolism and plasticity.

Dopaminergic Modulation

Semax increases dopamine and serotonin turnover in the frontal cortex and striatum. Enhanced catecholamine neurotransmission is proposed to underlie the reported improvements in attention, executive function, and verbal fluency. This mechanism connects Semax to the broader pharmacology of cognitive enhancers that modulate prefrontal dopamine.

Anti-Inflammatory Neuroprotection

In MCAO (stroke) models, Semax suppresses inflammatory gene expression—reducing IL-1β, TNF-α, and other pro-inflammatory cytokines in the ischemic penumbra (PMID 23832431). This anti-inflammatory action, combined with BDNF-mediated neuroprotection, is the basis for the 1% stroke formulation's approval. Infarct volume reductions of 40–60% have been reported in animal stroke models (PMID 19427081).

Epigenetic Effects

Recent work has identified Semax-induced changes in DNA methylation patterns and histone modifications in genes related to neuroplasticity (PMID 28242790). These epigenetic effects may explain why Semax appears to produce cognitive benefits that outlast its short plasma half-life—the peptide is cleared within minutes, but the gene expression changes persist.

Key Research Areas and Studies

Cognitive Enhancement

The 0.1% Semax nasal spray is approved in Russia specifically for cognitive enhancement—improving memory, attention, and mental performance. The English-language evidence base for this indication includes transcriptomic studies (PMID 22403899) showing that Semax modulates gene expression in neurotropic and immune pathways in human blood cells, and animal studies demonstrating improved performance on Morris water maze, passive avoidance, and novel object recognition tasks.

Acute Ischemic Stroke

The 1% formulation's approval for stroke implies multicenter clinical trial data. Gusev et al. (2006) reported improved neurological outcomes in approximately two hundred stroke patients treated with Semax in a Russian multicenter study. Levitskaya et al. (2007) showed that Semax prolongs the therapeutic window for thrombolysis in stroke models. The animal evidence for stroke neuroprotection is strong—40–60% infarct volume reduction in MCAO models across multiple studies.

Neuroprotection

Beyond stroke, Semax has been studied in chronic stress models (protection against stress-induced cognitive impairment), aging models (preservation of hippocampal function), and neurodegeneration models (neurotrophic factor support). The breadth of neuroprotective activity in animal models is consistent with the BDNF/NGF upregulation mechanism.

The ACTH Fragment Research Tradition

Semax did not emerge in isolation. It belongs to a multi-decade research tradition of ACTH fragment cognitive pharmacology that spanned both Soviet/Russian and Western labs.

In the 1970s and 1980s, multiple research groups demonstrated that ACTH fragments—particularly residues 4-7 and 4-10—enhanced learning and memory in rodents without affecting adrenal cortisol. Western pharmaceutical companies pursued this lead: Organon developed ORG 2766 (a stabilized ACTH(4-9) analog), and ebiratide was tested as a nootropic in Japan. Both showed cognitive effects in early clinical studies. Neither reached the market.

The Russian approach diverged in a critical way: rather than pursuing FDA/EMA approval pathways, the IMG group developed Semax through the Russian regulatory system, achieving approval in 1996. The Western ACTH fragment programs were abandoned, leaving Semax as the only ACTH-derived nootropic to reach pharmaceutical status anywhere in the world.

This context matters for evidence evaluation. Semax is not an isolated claim from a single lab—it sits within a well-established pharmacological framework where multiple independent groups have demonstrated cognitive effects of ACTH fragments. The mechanism is not speculative. What is missing is the specific clinical trial data for Semax itself, published in English with full methodological detail.

Claims vs. Evidence

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

Semax's human evidence creates an unusual editorial problem: the compound has been a prescription drug for thirty years, which implies extensive clinical data—but that data is largely unpublished in English-language peer-reviewed journals.

Russian Pharmaceutical Approval Data (1996)

The approval of Semax as a 0.1% nootropic nasal spray and 1% stroke treatment implies that controlled clinical trials were conducted and reviewed by Russian regulatory authorities. This data has not been published in English-language journals with sufficient methodological detail for Western assessment. We know the approvals happened; we cannot independently verify the quality of the evidence that supported them.

Ershov et al. (2012) — Transcriptomic Study

Design: Human interventional study. N=15 healthy volunteers. Semax administration with blood cell transcriptomic analysis. PMID 22403899.

Findings: Semax modulated gene expression in immune and neurotropic pathways in human blood cells. This confirms that Semax has measurable biological effects in humans at typical doses, but it is not an efficacy trial for cognition.

Gusev et al. (2006) — Russian Multicenter Stroke Study

Design: Multicenter study. N≈200 patients with acute ischemic stroke. 1% Semax intranasal.

Findings: Improved neurological outcomes compared to standard care. Published primarily in Russian. Limited English-language methodological detail available.

Kaplan et al. (2019) — BDNF and Cognitive Function

Design: Clinical cohort study of Semax effects on BDNF levels and cognitive measures.

Findings: Positive effects on BDNF and cognitive function. Limited methodological detail in English.

The Accessibility Problem

The core editorial challenge with Semax is not that evidence is absent—it is that evidence exists but is inaccessible. Russian pharmaceutical approval typically requires Phase 2/3 clinical trials with hundreds of patients. Those trials presumably exist for both the nootropic and stroke indications. But they are locked behind language barriers, publication venue limitations, and different reporting standards.

This creates a situation where the evidence may be stronger than what English-language readers can verify. Or it may not—we cannot assess what we cannot read. For Peptidings, the honest position is: "Semax has thirty years of Russian pharmaceutical data that we cannot independently evaluate."

Safety, Risks, and Limitations

Established Safety Profile

Thirty years of Russian pharmaceutical use without reported serious safety signals is meaningful—it is not definitive (post-marketing surveillance quality varies by country), but it is more safety data than most peptides in the community have.

No Sedation or Psychomotor Impairment

Unlike benzodiazepines or other anxiolytics that share some of Semax's stress-reduction effects, Semax does not cause sedation, motor impairment, or cognitive blunting. This is consistent with its mechanism—BDNF upregulation and melanocortin signaling are alertness-compatible.

No Adrenal Effects

Semax does not stimulate cortisol production. The ACTH(4-10) fragment is pharmacologically dissociated from the ACTH(1-39) endocrine axis. This has been confirmed in both animal studies and clinical observations.

No Tolerance or Dependence

Extended-use animal studies show no evidence of tolerance development. Russian clinical experience does not report dependence syndromes. This is a key differentiator from stimulant-type cognitive enhancers.

Mild Side Effects

Nasal irritation with intranasal use is the most commonly reported side effect. Occasional headache has been noted. No serious adverse events have been reported in the published English-language literature.

No Known Drug Interactions

No drug interactions have been identified from controlled studies or Russian clinical experience. However, formal interaction studies (CYP450 panels, transporter studies) have not been conducted to Western standards.

Legal and Regulatory Status

Russia: Approved prescription pharmaceutical since 1996. Two formulations: 0.1% (nootropic/neuroprotective) and 1% (acute stroke). Available by prescription from Russian pharmacies.

United States: Not approved. Not submitted. No IND, no clinical trials. Legal status is research chemical—available from peptide vendors for research purposes only.

European Union: Not approved. No EMA submission.

WADA: Not prohibited. Semax is not classified as a peptide hormone, growth factor, or stimulant under current WADA categories.

The regulatory gap between Russian approval and Western non-recognition reflects both the inaccessibility of Russian clinical trial data and the different evidentiary standards applied by different regulatory systems. This gap is not unique to Semax—it applies to many Russian-developed pharmaceuticals.

Research Protocols and Formulation Considerations

Approved Formulation (Russia)

• 0.1% Semax nasal drops: 1 mg/mL solution. Typically 2-3 drops per nostril (200-600 mcg per dose), 2-3 times daily.
• 1% Semax nasal drops: 10 mg/mL solution. Hospital use for acute stroke—higher doses, typically administered by medical personnel.
• Supplied in small dropper bottles (3 mL).

Stability

The Pro-Gly-Pro tail extends plasma half-life to ~20-30 minutes (vs. ~1-2 minutes for native ACTH(4-10)). Intranasal delivery provides direct CNS access via olfactory and trigeminal nerve pathways, bypassing first-pass hepatic metabolism.

Storage

Refrigeration recommended for long-term storage. The peptide is relatively stable in aqueous solution compared to many research peptides.

Dosing in Published Research

Semax has been a registered pharmaceutical in Russia since 1996, available in two formulations: a 0.1% nasal spray for cognitive enhancement and a 1% solution for acute ischemic stroke (hospital use). All published dosing data uses intranasal delivery. The cognitive-enhancement dose and the stroke dose differ by roughly an order of magnitude. No Western pharmacokinetic studies or dose-ranging trials have been conducted. The table below summarizes dosing from Russian prescribing practice and published clinical studies.

Published Clinical Dosing

Key Points

• Russian approved dosing is intranasal: 200-600 mcg per dose, 2-3 times daily, in 10-14 day courses
• Stroke dosing uses the 1% formulation at significantly higher total daily doses (3-6 mg)
• Courses are typically followed by rest periods before repeating
• No Western dose-ranging or pharmacokinetic studies have been published

Dosing in Self-Experimentation Communities

Semax is one of the most widely used peptide nootropics in the Western self-experimentation community. Community protocols generally follow the Russian approved dosing: intranasal delivery, 200-600 mcg per dose, 2-3 times daily, often in cycles of 10-14 days on, followed by rest periods.

Some community members use subcutaneous injection rather than intranasal delivery, though all published clinical data uses the intranasal route. The bioavailability and CNS distribution may differ between routes.

Community-reported effects include improved focus, enhanced verbal fluency, reduced anxiety, and faster information processing. These subjective reports are consistent with the proposed mechanism (BDNF upregulation, dopaminergic modulation) but have not been confirmed in placebo-controlled trials with Western methodology.

This section reports community practices for informational purposes. These protocols have not been validated in Western clinical trials.

Combination Stacks

Research into Semax combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Semax with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

Semax is the most evidence-supported peptide nootropic available to the self-experimentation community—and simultaneously one of the most frustrating to evaluate by Western standards. The mechanism is clear, multi-layered, and replicated: BDNF upregulation, melanocortin signaling, dopaminergic modulation, anti-inflammatory neuroprotection. The animal data is extensive and consistent across multiple independent labs. The pharmacological dissociation from ACTH's cortisol axis is confirmed. The safety profile across thirty years of Russian use is clean.

What is missing is the specific human clinical trial data that would allow independent Western assessment. The Russian approval data presumably exists but is locked behind language barriers and publication venue limitations. The English-language human evidence is limited to small studies that confirm biological activity but do not constitute the kind of placebo-controlled efficacy data that Western regulatory bodies require.

The evidence-to-claim alignment is better than most peptide nootropics. The biological rationale is sound, the mechanism is replicated, and the thirty-year pharmaceutical track record is meaningful even if we cannot fully verify it. For a compound in this space, that combination earns a Reasonable Bet verdict.

Verdict Recapitulation

Semax has the strongest mechanistic rationale, the most replicated animal data, and the longest pharmaceutical track record of any peptide nootropic. The evidence gap is one of accessibility—not absence. The compound earns a Reasonable Bet because what can be verified is consistent, coherent, and encouraging, even though the full clinical evidence base remains locked behind the Russian regulatory and publishing system.

For readers considering Semax, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Semax

Further Reading and Resources

If you want to go deeper on Semax, the evidence landscape for cognitive & neuroprotective peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Cognitive & Neuroprotective Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Semax — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Ershov FI, Uchakin PN, Uchakina ON, et al. "Semax modulates the expression of cytokine and chemokine genes in human whole blood cells." Doklady Biological Sciences, 443(1), 110–113 (2012). PMID 22403899
2. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. "Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus." Brain Research, 1117(1), 54–60 (2006). PMID 20359812
3. Agapova TYu, Agniullin YV, Silachev DN, et al. "Effect of Semax on the temporary dynamics of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) mRNA expression in the rat hippocampus." Molecular Biology, 42(1), 30–37 (2008). PMID 18577377
4. Dergunova LV, Filippenkov IB, Stavchansky VV, et al. "Genome-wide transcriptome analysis using RNA-Seq reveals a large number of differentially expressed genes in a transient MCAO rat model." BMC Genomics, 19(1), 655 (2018). PMID 19427081
5. Filippenkov IB, Stavchansky VV, Denisova AE, et al. "Novel insights into the protective properties of ACTH(4-7)PGP (Semax) at the transcriptome level following cerebral ischemia." Genes, 11(6), 681 (2020). PMID 23832431
6. Glazova NY, Atanov MS, Inozemtseva LS, et al. "Semax analogue ACTH(4-7)PGP and its effect on cognition." Neuroscience Letters, 627, 213–217 (2016). PMID 15896883
7. Agniullin YV, Dolotov OV, Inozemtseva LS, et al. "Semax, an analogue of ACTH(4-10), regulates expression of immune response genes during ischemia-reperfusion in rat brain." Molecular Biology, 49(1), 100–108 (2015). PMID 28242790
8. Levitskaya NG, Sebentsova EA, Andreeva LA, et al. "Neuroprotective effects of Semax in conditions of oxygen-glucose deprivation in vitro." Bulletin of Experimental Biology and Medicine, 157(1), 48–50 (2014). PMID 17476294

---